Sickle cell disease: clinical advances by the Murayama molecular hypothesis.
D000284:Administration, Oral; D000328:Adult; D000755:Anemia, Sickle Cell / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D000758:Anesthesia / Q000009:adverse effects; D001331:Automation; D003937:Diagnosis, Differential; D006453:Hemoglobinopathies / Q000175:diagnosis; D006454:Hemoglobins / Q000032:analysis / Q000378:metabolism; D006455:Hemoglobins, Abnormal / Q000032:analysis / Q000378:metabolism; D006801:Humans; D000860:Hypoxia / Q000517:prevention & control; D007275:Injections, Intravenous; D008297:Male; D008403:Mass Screening; D008854:Microscopy, Electron; D008961:Models, Structural; D013447:Sulfites; D013514:Surgical Procedures, Operative / Q000009:adverse effects; D014508:Urea / Q000008:administration & dosage / Q000627:therapeutic use
D006454:Hemoglobins; D006455:Hemoglobins, Abnormal; D013447:Sulfites; D014508:Urea